## Daisy Huynh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4613858/publications.pdf Version: 2024-02-01

		516215	525886
33	1,414	16	27
papers	citations	h-index	g-index
33	33	33	2855
all docs	docs citations	times ranked	citing authors

Πλιέν Ημγνιμ

#	Article	IF	CITATIONS
1	Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood, 2017, 129, 2429-2436.	0.6	214
2	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer, 2020, 1, 493-506.	5.7	209
3	Regulation of microRNAs in cancer metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 255-265.	3.3	132
4	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	2.9	123
5	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	5.8	98
6	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Reports, 2017, 19, 218-224.	2.9	92
7	The cancer glycome: Carbohydrates as mediators of metastasis. Blood Reviews, 2015, 29, 269-279.	2.8	91
8	Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression. Journal of Clinical Investigation, 2018, 128, 2487-2499.	3.9	80
9	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics, 2018, 17, 1454-1463.	1.9	70
10	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	5.8	53
11	Pyk2 promotes tumor progression in multiple myeloma. Blood, 2014, 124, 2675-2686.	0.6	51
12	Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation. Clinical Cancer Research, 2018, 24, 2430-2439.	3.2	44
13	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. Blood, 2015, 126, 23-23.	0.6	37
14	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia, 2018, 32, 1739-1750.	3.3	34
15	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood, 2018, 132, 2608-2612.	0.6	29
16	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS ONE, 2018, 13, e0204589.	1.1	17
17	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Advances, 2018, 2, 1272-1276.	2.5	9
18	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. Blood, 2016, 128, 197-197.	0.6	8

Daisy Huynh

#	Article	IF	CITATIONS
19	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. Blood, 2018, 132, 749-749.	0.6	6
20	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. Blood, 2015, 126, 502-502.	0.6	4
21	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. Blood, 2015, 126, 1770-1770.	0.6	4
22	A novel in vivo model for studying conditional dual loss of BLIMPâ€1 and p53 in Bâ€cells, leading to tumor transformation. American Journal of Hematology, 2017, 92, E138-E145.	2.0	3
23	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. Blood, 2016, 128, 1137-1137.	0.6	2
24	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. Blood, 2018, 132, 2603-2603.	0.6	1
25	Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination. Blood, 2014, 124, 4709-4709.	0.6	1
26	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. Blood, 2015, 126, 1793-1793.	0.6	1
27	Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression. Blood, 2018, 132, 3896-3896.	0.6	1
28	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance In Multiple Myeloma. Blood, 2013, 122, 121-121.	0.6	0
29	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. Blood, 2014, 124, 2056-2056.	0.6	0
30	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. Blood, 2015, 126, 1755-1755.	0.6	0
31	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. Blood, 2016, 128, 237-237.	0.6	0
32	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. Blood, 2016, 128, 4483-4483.	0.6	0
33	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. Blood, 2018, 132, 55-55.	0.6	0